홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Vorapaxar

HCID 10077130
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
618385-01-6
표준 SMILES
CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1
InChIKey
ZBGXUVOIWDMMJE-QHNZEKIYSA-N
분자식
C29H33FN2O4
평균 분자량
492.6 g/mol
단동위원소 질량
492.2424357

개요

Vorapaxar is a carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethynyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation. It has a role as a cardiovascular drug, a platelet aggregation inhibitor and a protease-activated receptor-1 antagonist. It is a carbamate ester, a lactone, a member of pyridines, an organofluorine compound and a naphthofuran. It is a conjugate base of a vorapaxar(1+).

이름 및 식별자

우선 이름
Vorapaxar
IUPAC
ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
영어명
Vorapaxar
분자식
C29H33FN2O4
분자량
492.58

이름 및 동의어

Vorapaxar618385-01-6SCH-530348SCH530348ZCE93644N2CHEBI:82702DTXSID201009336ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-dodecahydronaphtho[2,3-c]furan-6-yl]carbamatevorapaxarumethyl N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(5-(3-fluorophenyl)pyridin-2-yl)ethenyl)-1-methyl-3-oxo-dodecahydronaphtho(2,3-c)furan-6-yl)carbamateethyl N-((3R,3aS,4S,4aR,7R,8aR,9aR)-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)ethenyl)-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-naphtho(6,7-c)furan-7-yl)carbamateethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-naphtho[6,7-c]furan-7-yl]carbamate
이름 더 보기
MK-5348Vorapaxar (SCH 530348)[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-carbamic acid ethyl esterCS-2015CS-1663Voarapaxar2H5]-Vorapaxar7-Dihydrocapsaicin

물성

구조 계산 물성

XLogP
5.3
극성 표면적
77.5 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
6
회전 가능 결합 수
6
무거운 원자 수
36
형식 전하
0
복잡도
821

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Blood and blood forming organs -> Antithrombotic agents

물리화학적 성질

끓는 점
676 · 676.0±55.0 °C(Predicted)
밀도
1.24 · 1.24±0.1 g/cm3(Predicted)
저장 조건
-20 ° · Store at -20° C
용해도
24.65 mg/mL · ≥24.65 mg/mL in DMSO; insoluble in H2O; ≥10.64 mg/mL in EtOH with ultrasonic
물리적 상태
고체
산도 계수 (pKa)
12.49 · 12.49±0.60(Predicted)
색상
White to off-white
InChIKey
ZBGXUVOIWDMMJE-QHNZEKIYSA-N
SMILES
C(OCC)(=O)N[C@@H]1CC[C@]2([H])[C@@]([H])(C1)C[C@@]1([H])C(=O)O[C@H](C)[C@@]1([H])[C@H]2/C=C/C1=NC=C(C2=CC=CC(F)=C2)C=C1

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H371 (66.7%): May cause damage to organs [Warning Specific target organ toxicity, single exposure]

P260, P264, P270, P273, P308+P316, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesSTOT SE 2 (66.7%)

독성 정보

Hepatotoxicity · 1건

Vorapaxar is associated with a low rate of serum enzyme elevations during therapy that was similar to the rate that occurred with placebo or comparator therapies. In a large controlled trial in over 10,000 patients monitored over a 2 year period, ALT elevations above 5 times the upper limit of normal occurred in 1% of vorapaxar vs 1.4% of placebo patients. In pooled analyses of laboratory studies from more than 39,000 patients receiving vorapaxar or placebo, GGT was the only liver test that was abnormal in a higher proportion of patients receiving vorapaxar (3.8%) than placebo (3.3%), and there were no reports of liver related serious adverse events or clinically apparent liver injury. Thus, liver injury from vorapaxar must be rare, if it occurs at all.

안전 데이터

wgk
WGK 3
Hazard Classifications
Aquatic Acute 1Aquatic Chronic 1
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 2건

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein BindingVorapaxar is extensively bound (>99%) to human plasma proteins, such as human serum albumin.
Mechanism of Action · 1건

Vorapaxar inhibits platelet aggregation through the reversible antagonism of protease-activated receptor 1 (PAR-1), also known as thrombin receptor. PARs are a family of G-protein coupled receptors highly expressed on platelets and activated by serine protease activity of thrombin to mediate thrombotic response. By blocking PAR-1 activating, vorapaxar inhibits thrombin-induced platelet aggregation and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. Vorapaxar does not inhibit platelet aggregation induced by other agonists such as adenosine diphosphate (ADP), collagen or a thromboxane mimetic.

Biological Half-LifeVorapaxar has an effective half life of 3-4 days and an apparent terminal half life of 8 days.
Metabolism/MetabolitesVorapaxar is metabolized to its major circulating metabolite, M20, and its predominant metabolite excreted into feces, M19, by CYP3A4 and CYP 2J2.
FDA Pharmacological Classification · 5건

ZCE93644N2

VORAPAXAR

Established Pharmacologic Class [EPC] - Protease-activated Receptor-1 Antagonist

Mechanisms of Action [MoA] - Protease-activated Receptor-1 Antagonists

Vorapaxar is a Protease-activated Receptor-1 Antagonist. The mechanism of action of vorapaxar is as a Protease-activated Receptor-1 Antagonist.

MeSH Pharmacological Classification · 1건

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
RefChem:56276B01AC26DTXCID801436165Vorapaxar free baseMFCD16038876UNII-ZCE93644N2ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamateCHEMBL493982

데이터베이스 식별자

CAS
618385-01-6
PubChem CID
10077130
DTXSID
DTXSID201009336
ChEMBL
CHEMBL493982
ChEBI
CHEBI:82702
UNII
ZCE93644N2
EC Number
612-523-7
Nikkaji
J2.419.474D、J2.933.500A
Absorption, Distribution and Excretion · 3건

After oral administration, vorapaxar is rapidly absorbed and peak concentrations occur at a median tmax of 1 hour under faster conditions. Vorapaxar may be taken with or without food as ingestion with a high-fat meal did not result in meaningful changes in AUC. The mean absolute bioavailability is 100%.

Vorapaxar is primarily eliminated as its metabolite M19 through the feces (91.5%), and partially eliminated in the urine (8.5%).

424 L

응용 분야 · 1건

개요Vorapaxar is an orally bioavailable competitive antagonist of the proteinase-activated receptor (PAR1; Ki = 8.1 nM), also known as the thrombin receptor. It is selective for PAR1 over other PARs, as well as a number of GPCRs, ion channels, and receptors. It inhibits platelet aggregation induced by thrombin and haTRAP (IC50s = 47 and 25 nM, respectively). Vorapaxar (0.1 mg/kg, i.v.) completely inhibits platelet aggregation in cynomolgus monkeys ex vivo. Formulations containing vorapaxar are used in the prevention of thrombotic cardiovascular events.

추가 설명 · 1건

정의ChEBI: A carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethyny }-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation.